An observational study in Nausea and Vomiting, Postoperative, sponsored by Acacia Pharma Ltd. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-07.
Sponsored by Acacia Pharma Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd — none open to participants now, none under way, none of them phase 3. Postoperative Nausea and Vomiting · Acacia Pharma Ltd.
Among the 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd, this one is the only one that started in 2022, is the only observational one, and was the 9th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →None of the 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd is open now. The open studies under Postoperative Nausea and Vomiting, anywhere →
Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6
First in 2009; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 368 across the 9 interventional studies, 0 across the 1 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PROMPT (PONV Rescue Outcomes after AMisulPride Treatment) is an observational Phase IV study designed to evaluate real-world evidence in relation to the care continuum of Post Operative Nausea and Vomiting (PONV), as well as the effectiveness and safety of common pharmacologic rescue treatment regimens compared to IV amisulpride. There will be no predefined hypothesis regarding the magnitude of efficacy or safety of various treatment regimens from the cohorts observed. We are not proposing to directly recruit patients into this study.
Deidentified Electronic Health Record (EHR) information related to treatment of Post Operative Nausea and Vomiting (PONV) will be collected from academic and community hospitals throughout the United States. Deidentified EHRs for patients receiving treatment for PONV will be harvested in two cohorts:
Cohort 1, Rescue treatment according to the standard of care (SOC) at each study site prior to the introduction of IV amisulpride into clinical practice
Cohort 2, Rescue treatment IV amisulpride.
There is no planned investigational agent, prescribed treatment regimen, or mandated intervention, and treating clinicians will determine therapy for PONV according to clinical judgment. The projected inclusion over the course of this observational study is to enroll a total of 20,000+ patient EHRs evenly divided among those that received SOC and amisulpride treatment. Effectiveness and safety outcomes will be analyzed using standard statistical methods for observational studies. Comparison of deidentified patient EHRs in Cohort 1 and Cohort 2, including response rates, will be compiled and analyzed by an independent medical data analytics company.
In regard to a Quality Assurance (QA) Plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing, ArborMetrix performs QA as part of regular business. QA involves both automation testing and manual testing strategies including Failure Mode and Effects Analysis (FMEA), bounds testing and exploratory testing. Monitoring and auditing is done in line with their continued work toward HITRUST Compliance.
Regarding data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry, data validation is built into the registry configuration based on predefined rules as part of the data analytics and measures development. When receiving data in a batch, legal values, legal relationships, primary keys, constraints, duplicates, range, format, length, data type, parent-child relationship, variable name are all checked at both import and staging. The analytic process checks naming, ticket #, unit test (Statistical Analysis System (SAS), Structure Query Language (SQL)), integration, rules, range, consistency, outliers, missing and distribution. As part of the Risk and Reliability (RR) Adjustment, ArborMetrix checks missing, unique values, Observed to Expected (OE) ratio, C-stats, R squared and adjusted R squared. Report validation in the UI (User Interface), which in this case means the registry platform, compares reporting dictionary to analytic definition.
Regarding source data verification and assessing the accuracy, completeness, or representativeness of registry data, data for PROMPT is being pulled directly from the EMR system (i.e., external data sources) into the registry. No source data verification will be conducted.
Regarding Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management - there is no patient recruitment for PROMPT. It is an observational study. Information on data collection/management/analysis is answered in other questions. The change management system involves a Change Management Board, Change Management Request form outlining event spurring the change, requested date/time, engineers assigned, devices and/or systems being changed, a description of the change including technical details, impact, risk validation method and backout plan. The Request is peer reviewed and approved by leadership and technical personnel prior to implementation.
Plan for missing data to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results - As part of the data integration process, if variables necessary to meet measure criteria are deemed not available, Acacia will determine the next steps (i.e., remove measure, change measure criteria, etc.).
All adult patients (age ≥ 18 years) having Post-Operative Nausea and Vomiting (PONV) during their Post-Anesthesia Care Unit (PACU) stay, regardless of type of surgery, anesthesia, pre-medication, comorbidities, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients that received rescue treatment according to the standard of care (SOC).
Drug: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
Patients that received rescue treatment with IV amisulpride.
Drug: Amisulpride
Rescue Post-Operative Nausea and Vomiting (PONV) treatment
Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
Time to PACU Discharge
Time in mins from administration of first PONV rescue medication to discharge from post-anaesthesia care unit
Time frame: 24 hours
No study locations are listed for this record.
Start is estimated for Nov 2022; primary completion for Dec 2024, 25 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Postoperative Nausea and Vomiting →
Acacia Pharma Ltd